SynthesisDiabetes, obesity & metabolism2018
Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor tofogliflozin.
Synthesis in Diabetes, obesity & metabolism, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Sodium-glucose cotransporter-2 inhibitors use and the risk of gout: a systematic review and meta-analysis.Frontiers in endocrinology · 2023Pooled it
- Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor tofogliflozin.Diabetes, obesity & metabolism · 2018Pooled it
- Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial.European heart journal · 2022Trial
- Factors Influencing Change in Serum Uric Acid After Administration of the Sodium-Glucose Cotransporter 2 Inhibitor Luseogliflozin in Patients With Type 2 Diabetes Mellitus.Journal of clinical pharmacology · 2022Trial
- Dose-dependent reduction in body weight with LIK066 (licogliflozin) treatment in Japanese patients with obesity.Diabetes, obesity & metabolism · 2020Trial
- Effects of SGLT2 inhibitors on gout-related and cardiometabolic outcomes in patients with type 2 diabetes mellitus: a scoping review.Advances in rheumatology (London, England) · 2026Article
- Relationship between changes in uric acid levels and renal function during 12 months of treatment with luseogliflozin.Diabetology international · 2026Article
- Gout incidence in metformin versus sodium-glucose co-transporter-2 inhibitor users: a retrospective cohort study.Rheumatology (Oxford, England) · 2025Article
- SGLT2 inhibitors as metabolic modulators: beyond glycemic control in type 2 diabetes.Frontiers in endocrinology · 2025Review
- Sodium-Glucose Cotransporter 2 Inhibitors to Decrease the Uric Acid Concentration-A Novel Mechanism of Action.Journal of cardiovascular development and disease · 2023Review
- Dysuricemia-A New Concept Encompassing Hyperuricemia and Hypouricemia.Biomedicines · 2023Review
- Article
- Hypouricemia and Urate Transporters.Biomedicines · 2022Review
- Role and Risk Factors of Glycosylated Hemoglobin Levels in Early Disease Screening.Journal of diabetes research · 2021Article
- Contribution of Rare Variants of theGenetics · 2020Article
- Best (but oft-forgotten) practices: identifying and accounting for regression to the mean in nutrition and obesity research.The American journal of clinical nutrition · 2020Article
- Unaccounted for regression to the mean renders conclusion of article titled "Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor tofogliflozin" unsubstantiated.Diabetes, obesity & metabolism · 2018Article
- Characteristics of Dapagliflozin Responders: A Longitudinal, Prospective, Nationwide Dapagliflozin Surveillance Study in Korea.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2018Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An integrated analysis was performed with data from 4 phase 2 and phase 3 studies of tofogliflozin in which patients with type 2 diabetes mellitus received the sodium-glucose cotransporter 2 inhibitor tofogliflozin for up to 24 weeks. Sex differences, baseline haemoglobin A1c (HbA1c) and serum uric acid (UA) levels, and log
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.